UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Newly listed biotech firms perform poorly on KOSDAQ
Biotech companies that went public in the first half of this year have show...
by Nam Doo-hyun
|
2018-10-04 13:09
라인
‘Samsung C&T’s value to rise on BioLogics’ increased value’
Samsung C&T Corp., the parent company of Samsung Group, is likely to enjoy ...
by Nam Doo-hyun
|
2018-10-03 10:11
라인
More doctoral degree holders wanted at biotech ventures
Korean biotech venture companies are increasingly seeking more Ph.D.-qualif...
by Nam Doo-hyun
|
2018-10-02 14:40
라인
Which health agency had highest rise in female worker percentage?
Among health-related government agencies, the Korea Human Resource Developm...
by Nam Doo-hyun
|
2018-10-01 13:38
라인
Samil shares jump on anticipation of fatty liver treatment
Shares of Samil Pharmaceutical spiked on Thursday on investors’ anticipatio...
by Nam Doo-hyun
|
2018-09-28 14:21
라인
Genexine wins nod for immunotherapy trial in combo treatment
Pharmaceutical industry officials are pinning high hopes on combination tre...
by Nam Doo-hyun
|
2018-09-27 11:25
라인
Korea’s drug exports continue to rise in August
The exports of Korean pharmaceutical products continued to expand and excee...
by Nam Doo-hyun
|
2018-09-20 14:23
라인
‘Many Korean hospitals operating in China remain unlawful’
Korean hospitals continue to enter the Chinese market, but most of them are...
by Nam Doo-hyun
|
2018-09-20 14:22
라인
Shares of newly listed biotech firms surge
The stocks of three biotech companies that went public in the second half h...
by Nam Doo-hyun
|
2018-09-19 18:30
라인
‘If you can’t avoid healthcare regulation, enjoy it’
The government regulation is the biggest hurdle for healthcare business but...
by Nam Doo-hyun
|
2018-09-19 14:43
라인
‘Smart hospitals’ to reduce repetitive nursing work
New digital healthcare technologies will significantly reduce repetitive wo...
by Nam Doo-hyun
|
2018-09-17 15:48
라인
Nature Cell shares spike despite investment alert warning
Industry watchers are looking for answers why shares of Nature Cell have be...
by Nam Doo-hyun
|
2018-09-14 16:08
라인
Female workforce scarce in top 15 local pharmaceuticals
Among the top 15 domestic drug companies, Kwangdong Pharmaceutical has the ...
by Nam Doo-hyun
|
2018-09-13 11:41
라인
GC Cell shares spike on winning FDA nod for Immuncell-LC
Stock prices of GC Cell and ToolGen went in the opposite direction on Wedne...
by Nam Doo-hyun
|
2018-09-12 16:05
라인
‘Xgeva reduces risk of bone problems in solid tumor patients’
Amgen Korea’s Xgeva (ingredient: denosumab), a therapy for bone metastases ...
by Nam Doo-hyun
|
2018-09-12 12:23
라인
Hepatitis C patients wait for Maviret’s arrival
Korean physicians and patients have expressed high expectations for AbbVie ...
by Nam Doo-hyun
|
2018-09-11 16:16
라인
‘ToolGen’s KOSDAQ listing might be in peril’
ToolGen, a local biotech firm specialized in gene editing, has been mired i...
by Nam Doo-hyun
|
2018-09-10 14:59
라인
Opdivo-Yervoy okayed as first-line treatment for renal cell carcinoma
The Korean government has approved Ono Pharma Korea and Bristol-Myers Squib...
by Nam Doo-hyun
|
2018-09-06 15:02
라인
CrystalGenomics to export novel drug Acelex to Brazil soon
Acelex, the nation’s 22nd novel drug treating degenerative arthritis, is so...
by Nam Doo-hyun
|
2018-09-04 11:18
라인
Korea’s drug exports to China rebound this year
Korea’s drug exports to China turned around this year amid the easing of tr...
by Nam Doo-hyun
|
2018-08-31 13:10
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top